AI assistant
IMUGENE LIMITED — Capital/Financing Update 2022
Jan 30, 2022
65124_rns_2022-01-30_f096f3ca-1e8c-4658-9831-4853716d94e5.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX Announcement
==> picture [116 x 42] intentionally omitted <==
Issue of Options under the Employee Share Option Plan (ESOP)
SYDNEY, Australia, 31 January 2022: Imugene Limited (ASX:IMU), an immuno-oncology company, will issue 6.5 million unlisted options to executives under the Company’s Employee Share Option Plan (ESOP) as part of the Company’s salary review process.
Included in the above 6.5 million options are 3 million unlisted options proposed to be issued to Leslie Chong as MD & CEO (subject to future shareholder approval), vesting in equal parts over 3 years with a strike price of $0.40 each. Further details of the proposed 3 million issue will be included in the explanatory memorandum relating to the next shareholder meeting. The date of such a meeting has not been set and the resolution may be put to shareholders at the Annual General Meeting later in the calendar year.
Details of the 3.5 million options not subject to shareholder approval will be advised in an Appendix 3G to be released following this announcement.
For more information please contact:
Paul Hopper Executive Chairman [email protected]
Investor Enquires [email protected]
Media Enquires
Matt Wright
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts
IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM [email protected]
with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Release authorised by the Executive Chairman
Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia
2
IMUGENE LIMITED ACN 009 179 551